

# Dicerna

Dicerna Pharmaceuticals  
Investor Relations Department  
87 Cambridgepark Drive  
Cambridge, MA 02140  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

## NASDAQ: DRNA

|               |  |
|---------------|--|
| Last Trade:   | 11.57  |
| Trade Time:   | 3:17 PM ET<br>Feb 21, 2018                         |
| Change:       | -0.25 <span style="color: red;">↓</span> (-2.115%) |
| Day Range     | 11.54 - 12.32                                      |
| 52-Week Range | 2.52 - 12.01                                       |
| Volume        | 364,594  |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The Company is using its proprietary GalXC RNAi technology platform to build a broad pipeline in these therapeutic areas.

[Dicerna Corporate Fact Sheet\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Feb 6, 2018*  
[Dicerna to Participate in Upcoming Investor Conferences](#)

*Jan 23, 2018*  
[Dicerna to Present at Noble Capital Markets' NobleCon14](#)

*Dec 14, 2017*  
[Dicerna Announces Pricing of Follow-On Public Offering of Common Stock](#)

*Dec 13, 2017*  
[Dicerna Announces Proposed Public Offering of Common Stock](#)

*Dec 7, 2017*  
[Dicerna Announces First Human Dosed in Phase 1 Clinical Trial of DCR-PHXC for Treatment of All Forms of Primary Hyperoxaluria](#)

## Financials [\[ View all \]](#)

*Mar 30, 2017*  
[Annual Report \(10-K\)](#)

*May 23, 2017*  
[Proxy Statement \(DEF 14A\)](#)

*Nov 2, 2017*  
[Quarterly Report \(10-Q\)](#)

*Aug 10, 2017*  
[Quarterly Report \(10-Q\)](#)

*May 8, 2017*  
[Quarterly Report \(10-Q\)](#)